SCHEMBL1551099

SCHEMBL1551099

[c]1[nH]ccc1-n1cccc1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11053972 0.68
SCHEMBL4515850 0.62 ADRB1 (0.44)
SCHEMBL8410646 0.61 LMNA (0.41)
SCHEMBL15421672 0.60 MEN1 (0.30)
SCHEMBL293612 0.59 KDM4E (0.34)
SCHEMBL15009410 0.55 CA1 (0.31)
SCHEMBL8495575 0.55
SCHEMBL13661859 0.53 KDM4E (0.36)
SCHEMBL17103386 0.50
SCHEMBL3075460 0.49 KDM4E (0.35)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9499467-B2 Ortho-fluoro substituted compounds for the treatment of metabolic diseases CALDAN THERAPEUTICS LIMITED (GB) 2016-11-22 US claimed
US-20140058125-A1 ORTHO-FLUORO SUBSTITUTED COMPOUNDS FOR THE TREATMENT OF METABOLIC DISEASES SYDDANSK UNIVERSITET (DK) 2014-02-27 US claimed
EP-2694465-A1 ORTHO-FLUORO SUBSTITUTED COMPOUNDS FOR THE TREATMENT OF METABOLIC DISEASES Syddansk Universitet (DK) 2014-02-12 EP claimed
US-8586607-B2 Compounds for the treatment of metabolic diseases SYDDANSK UNIVERSITET (DK) 2013-11-19 US claimed
WO-2012136221-A1 ORTHO-FLUORO SUBSTITUTED COMPOUNDS FOR THE TREATMENT OF METABOLIC DISEASES SYDDANSK UNIVERSITET (DK) 2012-10-11 WO claimed
EP-2313360-B1 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISEASES UNIV SYDDANSK (DK) 2012-09-05 EP claimed
US-20110152315-A1 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISEASES SYDDANSK UNIVERSITET 2011-06-23 US claimed
EP-2313360-A1 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISEASES Syddansk Universitet (DK) 2011-04-27 EP claimed
WO-2010012650-A1 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISEASES SYDDANSK UNIVERSITET (DK) 2010-02-04 WO claimed
US-10836688-B2 Organic reactions carried out in aqueous solution in the presence of a hydroxyalkyl(alkyl)cellulose or an alkylcellulose ABBVIE INC. (US) 2020-11-17 US disclosed
US-20200148610-A1 ORGANIC REACTIONS CARRIED OUT IN AQUEOUS SOLUTION IN THE PRESENCE OF A HYDROXYALKYL(ALKYL)CELLULOSE OR AN ALKYLCELLULOSE ABBVIE INC. 2020-05-14 US disclosed
EP-2962687-B1 TAU AGGREGATION INHIBITOR THE DOSHISHA (JP) 2019-06-05 EP disclosed
US-9907799-B2 Tau aggregation inhibitor THE DOSHISHA (JP) 2018-03-06 US disclosed
US-9809604-B2 DGAT1 inhibitor and preparation method and use thereof QINGDAO HUANGHAI PHARMACEUTICAL CO., LTD. (CN) 2017-11-07 US disclosed
WO-2008075196-A1 BENZIMIDAZOLE DERIVATIVES PFIZER PRODUCTS INC. (US) 2008-06-26 WO disclosed
EP-1549646-A4 PIPERIDINE DERIVATIVES AMGEN INC (US) 2008-05-21 EP disclosed
US-20060229311-A1 Isatine derivatives with neurotrophic activity GROENBORG METTE 2006-10-12 US disclosed
EP-1549646-A2 PIPERIDINE DERIVATIVES Tularik Inc. (US) 2005-07-06 EP disclosed
WO-2004028459-A2 PIPERIDINE DERIVATIVES TULARIK INC. (US) 2004-04-08 WO disclosed
US-4950662-A ANTIBIOTIC OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1990-08-21 US disclosed